<DOC>
	<DOCNO>NCT01829659</DOCNO>
	<brief_summary>This study do assess effect CTP inhibitor function platelet ( cell within blood involve formation blood clot ) assess whether respond ticagrelor well enough prevent formation blood clot within stent site angioplasty perform . Recent study look racial difference affect platelet reactivity , way blood clot . But study look way different racial background affect way blood form clot . Minorities , African-Americans underrepresented . Therefore , conduct platelet reactivity study good understand difference drug affect African-Americans affect Caucasian patient undergo percutaneous coronary intervention receive ticagrelor . These data compare historical control Caucasian patient underwent similar platelet function testing .</brief_summary>
	<brief_title>The ACS Ethnicity Platelet Function Study</brief_title>
	<detailed_description />
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Female ( post menopausal surgically sterile ) and/or male age 18 year old Presenting ACS fulfil follow : 1 . Symptoms new ECG change ( ST segment elevation depression least 1 mm 2 contiguous lead EKG ) 2 . Elevation biomarkers ( CKMB ≥2 ULN troponin ≥ ULN ) Selfidentified AfricanAmerican Treatment 75100mg ASA daily Any indication ( atrial fibrillation , mitral stenosis prosthetic heart valve , PE , DVT ) antithrombotic treatment study period . Fibrinolytic therapy within 48 hour randomization Concomitant therapy drug possible interaction ticagrelor . ( concomitant therapy strong cytochrome P450 3A inhibitor inducer ) Increased bleed risk include : recent ( &lt; 30 day ) GI bleeding , history intracranial , intraocular , retroperitoneal , spinal bleeding , recent ( &lt; 30 day dose ) major trauma , sustain uncontrolled hypertension ( systolic blood pressure [ SBP ] &gt; 180mmHg diastolic blood pressure [ DBP ] &gt; 100mmHg ) , history hemorrhagic disorder increase risk bleeding , platelet count le 100,000 mm3 hemoglobin &lt; 10 g/dL . Any history hemorrhagic stroke . Contraindication reason ASA ticagrelor administer ( e.g. , hypersensitivity , active bleeding , major surgery within 30 day dose ) . Severe renal failure ( creatinine clearance &lt; 30mL/min patient require dialysis ) History moderate severe hepatic impairment aspartate amino transferace , alanine amino transferase total bilirubin &gt; 1.5 x upper limit reference range . Pregnant lactating woman . Patients receive glycoprotein IIb/IIIa inhibitor &lt; 8 hour platelet reactivity testing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>